Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Articles|February 1, 2014
- Pharmaceutical Technology-02-01-2014
- Volume 2014 Supplement
- Issue 1
Jubilant HollisterStier
Jubilant HollisterStier
Advertisement
Jubilant HollisterStier
Contract Manufacturing & Services Division U.S.A. – Canada – India
3525 N. Regal St.
Spokane, WA, U.S.A. 99207
tel. 800.655.5329
Description
Jubilant HollisterStier Contract Manufacturing is an integrated contract manufacturer, able to manufacture sterile injectable, solid and semi solid dosage forms. Our facilities across North America and India provide specialized manufacturing services for the pharmaceutical and biopharmaceutical industries. We provide a full-range of support and services to streamline the manufacturing process.
- Sterile Injectable Fill/Finish (clinical to commercial)
- Lyophilization (clinical to commercial)
- Sterile Ophthalmics & Otics
- Non-Sterile Topicals & Liquids
- Solid Dosage
- Multiple Formats (vials, ampoules, tablets, capsules, bottles, tubes, jars, applicators)
Jubilant HollisterStier is registered with such Regulatory authorities as the FDA (CDER, CBER) EMA, ANVISA, PMDA, and Health Canada.
Articles in this issue
over 12 years ago
Global Markets Demand Local Knowledgeover 12 years ago
Clinical-Trial Material Supply by Way of Shanghaiover 12 years ago
Managing Clinical Development Risk: Pharma and CRO Reportover 12 years ago
A New Dawn for Western CMOsover 12 years ago
Partnership Models Structure R&D Changeover 12 years ago
Outsourcing Trends in Biopharmaceutical Manufacturingover 12 years ago
Ensuring Sound Bioanalytical Methods TransferAdvertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
3
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
4
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
5